List view / Grid view
27 May 2015 | By Victoria White
Primary results from a Phase 3 study demonstrates a significantly higher DRR in patients with metastatic melanoma receiving the talimogene laherparepvec...
27 May 2015 | By Victoria White
The EC has granted marketing authorisation for tolvaptan for the treatment of ADPKD in adults who have chronic kidney disease (CKD)...
27 May 2015 | By Victoria White
The global market value for advanced wound dressings will increase to reach $3.51 billion by 202, according to research and consulting firm GlobalData...
27 May 2015 | By Victoria White
Helsinn Group has announced that the European Commission has approved ALOXI injection for the prevention of acute CINV in children aged one to six months...
27 May 2015 | By Victoria White
Eisai has received a positive opinion from the EMA’s CHMP for the use of Fycompa for the adjunctive treatment of PGTC seizures...
27 May 2015 | By Victoria White
Aeterna Zentaris has received advice from the EMA regarding the development plan for the new confirmatory Phase 3 clinical study of Macrilen in AGHD...
26 May 2015 | By Victoria White
A genetically engineered herpes virus, T-VEC, can halt the progression of skin cancer by killing cancer cells and sparking the immune system into action...
26 May 2015 | By Victoria White
The South Asian Health Foundation (SAHF) has been named ‘Diabetes Team of the Year’ at the prestigious 2015 BMJ Awards...
26 May 2015 | By Victoria White
Mast Therapeutics has initiated an open-label, multicentre Phase 3 extension study of vepoloxamer (MST-188) in sickle cell disease, referred to as "EPIC-E"...
26 May 2015 | By Victoria White
AbbVie has completed the acquisition of Pharmacyclics, enhancing AbbVie's scientific and commercial presence in the haematological oncology market...
26 May 2015 | By Victoria White
Data for anti-epileptic drug eslicarbazepine acetate shows it to be effective and well tolerated in elderly people with partial onset seizures (POS)...
26 May 2015 | By Victoria White
Faron has entered into strategic agreements with CMS and A&B Ltd for the development and commercialisation of Traumakine for the treatment of ARDS...
26 May 2015 | By Victoria White
CHMP has adopted a positive opinion of Simponi for the treatment of adults with severe active non-radiographic axial spondyloarthritis...
26 May 2015 | By Victoria White
Amgen has announced the termination of its co-development and commercialisation agreement with AstraZeneca for brodalumab...
22 May 2015 | By Victoria White
The CHMP has adopted a positive opinion for the marketing authorisation of Amgen’s Repatha for use in certain patients with high cholesterol...
